RET and carcinoma: Patients with RET fusion-positive PTCs were significantly younger than patients with BRAF V600E and RAS-mutated carcinomas (P < 0.001) and had significantly larger tumor than patients with the BRAF V600E-mutated carcinomas (P < 0.001).